Copanlisib Yields Responses in Relapsed/Refractory Non-Hodgkin Lymphoma

This video reviews results of the phase II CHRONOS-1 trial, a single-arm study evaluating the investigational agent copanlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma. (Source: CancerNetwork)

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2oG37Sg
via IFTTT